CRISPR gene editing firms clear investors’ confusion

Playing buy and sell games with the CRISPR gene editing stocks is sometimes based on scientific articles that meant to caution about possible problems or by patents that were given to some Universities and denied it to others and vice versa. Different Universities back different CRISPR gene-editing firms, which constituted a reason for the volatility of the gene-editing stocks.

Finally, CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Caribou Biosciences published an article that clarifies their position, informing investors and others about the reality of what’s going on . . .

This content is for paid subscribers.
Please click here to subscribe or log in.